Effect of ciprofol with etomidate on the occurrence of hypotension in elderly patients undergoing upper gastrointestinal endoscopy: a prospective randomized controlled study
Authors:
Open Access
- 24 March 2026
- journal article
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26
Abstract
Ciprofol is increasingly used for endoscopic sedation due to its reduced injection pain, but evidence regarding its safety when combined with etomidate in elderly patients remains limited. This study evaluated the efficacy and safety of ciprofol–etomidate compared with ciprofol alone and propofol–etomidate in elderly patients undergoing upper gastrointestinal endoscopy. In this randomized controlled trial, 402 patients aged ≥ 60 years scheduled for upper gastrointestinal endoscopy were assigned to one of three groups: ciprofol–etomidate (EC: 0.3 mg/kg ciprofol + 0.12 mg/kg etomidate), ciprofol (C: 0.4 mg/kg) alone, or propofol–etomidate (EP: 1.2 mg/kg propofol + 0.12 mg/kg etomidate). All patients received remifentanil 0.3 µg/kg before sedation. The primary outcome was hypotension incidence. Secondary outcomes included sedation success, vital signs, and other adverse events. Hypotension incidence differed significantly among groups (EC: 64.5%, C: 80.9%, EP: 75.2%; p = 0.008), with a lower rate in the EC group versus the C group (p = 0.003). Injection pain was rare in both EC (0.7%) and C (1.5%) groups compared with EP (9.0%; p < 0.001). Induction time was longer in EC and C groups than in EP. Recovery and discharge times were prolonged in the C group compared with EP. Other adverse events, including bradycardia, hypoxemia, nausea, vomiting, dizziness, and tremors, did not differ significantly among groups. The combination of ciprofol and etomidate offers effective sedation, reducing hypotension compared with ciprofol alone and injection pain compared with propofol–etomidate, and may therefore represent a safer alternative for elderly patients undergoing upper gastrointestinal endoscopy. Chinese Clinical Trial Registry, ChiCTR2300077770 (date: 20/11/2023). The online version contains supplementary material available at 10.1186/s12871-026-03767-2.Keywords
Funding Information
- Hunan Clinical Medical Research Center for Acute and Chronic Pain (2023SK4014)
- Natural Science Foundation of Hunan Province (2024JJ7443)
This publication has 31 references indexed in Scilit:
- Compatibility and Stability of Cipepofol (Ciprofol) and Etomidate Mixture for Intravenous AnesthesiaCurrent Therapeutic Research, 2025
- Efficacy and safety of Ciprofol compared with Propofol during general anesthesia induction: A systematic review and meta-analysis of randomized controlled trials (RCT)Journal of Clinical Anesthesia, 2024
- Efficacy and safety of Ciprofol for procedural sedation and anesthesia in non-operating room settingsJournal of Clinical Anesthesia, 2023
- Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 StudyCNS Drugs, 2022
- Hypotension during propofol sedation for colonoscopy: a retrospective exploratory analysis and meta-analysisBritish Journal of Anaesthesia, 2021
- Etomidate and its Analogs: A Review of Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 2021
- Recent Developments in Drugs for GI Endoscopy SedationDigestive Diseases and Sciences, 2020
- Propofol infusion syndrome: a structured literature review and analysis of published case reportsBritish Journal of Anaesthesia, 2019
- Clinical Pharmacokinetics and Pharmacodynamics of PropofolClinical Pharmacokinetics, 2018
- Etomidate plus propofol versus propofol alone for sedation during gastroscopy: a randomized prospective clinical trialSurgical Endoscopy, 2016